Role of channel activation in cognitive enhancement mediated by α7 nicotinic acetylcholine receptors

被引:61
作者
Briggs, Clark A. [1 ]
Gronlien, Jens Halvard [1 ]
Curzon, Peter [1 ]
Timmermann, Daniel B. [2 ]
Ween, Hilde [1 ]
Thorin-Hagene, Kirsten [1 ]
Kerr, Paige [1 ]
Anderson, David J. [1 ]
Malysz, John [1 ]
Dyhring, Tino [2 ]
Olsen, Gunnar M. [2 ]
Peters, Dan [2 ]
Bunnelle, William H. [1 ]
Gopalakrishnan, Murali [1 ]
机构
[1] Abbott Labs, Neurosci Res, Abbott Pk, IL 60064 USA
[2] NeuroSearch AS, Drug Discovery, Ballerup, Denmark
关键词
nicotinic acetylcholine receptor; ligand-gated ion channels; desensitization; functional systems; learning and memory; biopharmaceuticals; ALLOSTERIC MODULATOR; ENHANCING PROPERTIES; HIPPOCAMPAL-NEURONS; SUBUNIT COMPOSITION; IN-VITRO; RAT; AGONIST; BRAIN; METHYLLYCACONITINE; EXPRESSION;
D O I
10.1111/j.1476-5381.2009.00426.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and purpose: Several agonists of the alpha 7 nicotinic acetylcholine receptor (nAChR) have been developed for treatment of cognitive deficits. However, agonist efficacy in vivo is difficult to reconcile with rapid alpha 7 nAChR desensitization in vitro; and furthermore, the correlation between in vitro receptor efficacy and in vivo behavioural efficacy is not well delineated. The possibility that agonists of this receptor actually function in vivo as inhibitors via desensitization has not been finally resolved. Experimental approach: Two structurally related alpha 7 nAChR agonists were characterized and used to assess the degree of efficacy required in a behavioural paradigm. Key results: NS6784 activated human and rat alpha 7 nAChR with EC(50)s of 0.72 and 0.88 mu M, and apparent efficacies of 77 and 97% respectively. NS6740, in contrast, displayed little efficacy at alpha 7 nAChR (< 2% in oocytes, < 8% in GH4C1 cells), although its agonist-like properties were revealed by adding a positive allosteric modulator of alpha 7 nAChRs or using the slowly desensitizing alpha 7V274T receptor. In mouse inhibitory avoidance (IA) memory retention, NS6784 enhanced performance as did the 60% partial agonist A-582941. In contrast, NS6740 did not enhance performance, but blocked effects of A-582941. Conclusions and implications: Collectively, these findings suggest that a degree of alpha 7 nAChR agonist efficacy is required for behavioural effects in the IA paradigm, and that such behavioural efficacy is not due to alpha 7 nAChR desensitization. Also, a partial agonist of very low efficacy for this receptor could be used as an inhibitor, in the absence of alpha 7 nAChR antagonists with favourable CNS penetration.
引用
收藏
页码:1486 / 1494
页数:9
相关论文
共 50 条
  • [1] α-Bungarotoxin- and methyllycaconitine-sensitive nicotinic receptors mediate fast synaptic transmission in interneurons of rat hippocampal slices
    Alkondon, M
    Pereira, EFR
    Albuquerque, EX
    [J]. BRAIN RESEARCH, 1998, 810 (1-2) : 257 - 263
  • [2] ALKONDON M, 1992, MOL PHARMACOL, V41, P802
  • [3] [3H]A-585539 [(1S,4S)-2,2-Dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a novel high-affinity α7 neuronal nicotinic receptor agonist:: Radioligand binding characterization to rat and human brain
    Anderson, David J.
    Bunnelle, William
    Surber, Bruce
    Du, Jia
    Surowy, Carol
    Tribollet, Eliane
    Marguerat, Anouk
    Bertrand, Daniel
    Gopalakrishnan, Murali
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 324 (01) : 179 - 187
  • [4] Central role of α7 nicotinic receptor in differentiation of the stratified squamous epithelium
    Arredondo, J
    Nguyen, VT
    Chernyavsky, AI
    Bercovich, D
    Orr-Urtreger, A
    Kummer, W
    Lips, K
    Vetter, DE
    Grando, SA
    [J]. JOURNAL OF CELL BIOLOGY, 2002, 159 (02) : 325 - 336
  • [5] Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways
    Bitner, Robert S.
    Bunnelle, William H.
    Anderson, David J.
    Briggs, Clark A.
    Buccafusco, Jerry
    Curzon, Peter
    Decker, Michael W.
    Frost, Jennifer M.
    Gronlien, Jens Halvard
    Gubbins, Earl
    Li, Jinhe
    Malysz, John
    Markosyan, Stella
    Marsh, Kennan
    Meyer, Michael D.
    Nikkel, Arthur L.
    Radek, Richard J.
    Robb, Holly M.
    Timmermann, Daniel
    Sullivan, James P.
    Gopalakrishnan, Murali
    [J]. JOURNAL OF NEUROSCIENCE, 2007, 27 (39) : 10578 - 10587
  • [6] The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents
    Boess, Frank G.
    De Vry, Jean
    Erb, Christina
    Flessner, Timo
    Hendrix, Martin
    Luithle, Joachim
    Methfessel, Christoph
    Riedl, Bernd
    Schnizler, Katrin
    van der Staay, Franz-Josef
    van Kampen, Marja
    Wiese, Welf Burkhard
    Koenig, Gerhard
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (02) : 716 - 725
  • [7] α7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues
    Briggs, C. A.
    Schrimpf, M. R.
    Anderson, D. J.
    Gubbins, E. J.
    Gronlien, J. H.
    Hakerud, M.
    Ween, H.
    Thorin-Hagene, K.
    Malysz, J.
    Li, J.
    Bunnelle, W. H.
    Gopalakrishnan, M.
    Meyer, M. D.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (05) : 1054 - 1061
  • [8] Untranslated region-dependent exclusive expression of high-sensitivity subforms of α4β2 and α3β2 nicotinic acetylcholine receptors
    Briggs, CA
    Gubbins, EJ
    Marks, MJ
    Putman, CB
    Thimmapaya, R
    Meyer, MD
    Surowy, CS
    [J]. MOLECULAR PHARMACOLOGY, 2006, 70 (01) : 227 - 240
  • [9] Effect of MK-801 at the human alpha 7 nicotinic acetylcholine receptor
    Briggs, CA
    McKenna, DG
    [J]. NEUROPHARMACOLOGY, 1996, 35 (04) : 407 - 414
  • [10] Gain of function mutation of the α7 nicotinic receptor:: distinct pharmacology of the human α7V274T variant
    Briggs, CA
    McKenna, DG
    Monteggia, LM
    Touma, E
    Roch, JM
    Arneric, SP
    Gopalakrishnan, M
    Sullivan, JP
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 366 (2-3) : 301 - 308